Streetbeat News

Products Services

DXBRF

BellRock Brands Inc. (OTCEM: DXBRF) (CSE:BRCK) has entered into a licensing agreement with Dark Horse Medicinals, LLC to bring the Mary's Medicinals and Dixie Brands to Arkansas. Mary's Medicinals will be available in Arkansas in the fourth quarter of 2023, with the launch of Dixie products expected to follow in 2024. Dixie Brands is also launching several new product lines in Missouri under a licensing agreement with BRB Missouri, LLC.

Portfolio Pulse from Jelena Martinovic

October 24, 2023 | 2:46 pm

CLSK

Shares of CleanSpark Inc (NASDAQ:CLSK) are trading higher by 17.7% after Bitcoin reached $35,000 for the first time since 2022. The rise in Bitcoin's price increases the profitability of cryptocurrency mining, potentially increasing demand for CleanSpark's services. The anticipation of a potential Bitcoin ETF, which suggests greater institutional interest in cryptocurrencies, could also attract more investors to the cryptocurrency market, further increasing demand for CleanSpark's services.

Portfolio Pulse from Henry Khederian

October 24, 2023 | 2:21 pm

INM

InMed Pharmaceuticals Inc (NASDAQ:INM) shares soared after the company announced it has selected a lead Alzheimer's drug candidate following positive proof-of-concept study data. The company's INM-901 demonstrated unique pharmacological effects in Alzheimer's disease in preclinical studies. The company now plans to advance the Alzheimer's candidate into its pharmaceutical drug development program.

Portfolio Pulse from Adam Eckert

October 24, 2023 | 2:20 pm

INM

InMed Pharmaceuticals has announced the selection of a lead Alzheimer's drug candidate following proof-of-concept study data, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 2:19 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc., is planning to enhance ChromeOS accessibility settings by incorporating a unique face-tracking feature. This feature will allow users to control cursor and keyboard movements via facial expressions. The face-tracking option has been added to the settings on ChromeOS version 120, but it's not yet active. This development is part of Google's ongoing efforts to make technology more accessible and user-friendly.

Portfolio Pulse from Benzinga Neuro

October 24, 2023 | 1:51 pm

AMD

NVDA

The Asus ROG Flow X13, a gaming laptop, is powered by Advanced Micro Devices, Inc.'s (AMD) Ryzen 7000 series processor and Nvidia Corp.'s (NVDA) RTX 40 series graphics. The laptop is praised for its performance, portability, and versatility, excelling in tasks such as document editing, media consumption, multitasking, and gaming. However, concerns are raised about its battery life and the need to adjust gameplay settings.

Portfolio Pulse from Rounak Jain

October 24, 2023 | 1:43 pm

IBKR

Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers (NASDAQ:IBKR), will be a panelist at Benzinga's Fintech Deal Day & Awards event on Nov. 13. Sanders has over two decades of experience at Interactive Brokers and has helped the company achieve over $1.8 billion in net income. In 2022, IBKR launched the IBKR GlobalTrader, a mobile trading application that allows investors to trade stocks and options worldwide and access cryptocurrency through Paxos Trust Company.

Portfolio Pulse from Khyathi Dalal

October 24, 2023 | 1:39 pm

ADM

BYND

Archer-Daniels-Midland's CFO, Vikram Luthar, has announced that the company is shifting its plant-based protein ingredients production to higher demand products due to a slump in demand for meat alternatives.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 1:26 pm

ROMJF

Rubicon Organics Inc. is launching Wildflower brand edibles with minor cannabinoids in four flavors. The gummies are made with all-natural ingredients and are vegan and gluten-free. The products will be available for ordering in British Columbia starting October 2023, in Alberta in November 2023, and in Ontario in February 2024. Rubicon’s shares traded 2.4465% lower at $0.319 per share after the market close on Monday.

Portfolio Pulse from Jelena Martinovic

October 24, 2023 | 1:18 pm

ANVS

Annovis Bio, Inc. (NYSE:ANVS) presented promising results from its drug development for neurodegenerative diseases at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 conference. The drug, buntanetap, inhibits the production of neurotoxic proteins responsible for Alzheimer's and Parkinson's diseases. The findings have been replicated in all human phase I and II trials to date, demonstrating decreased levels of toxic proteins, improved axonal transport, reduced inflammation, and neuroprotection. The company is currently in phase III trials and discussing the path forward with the FDA.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2023 | 1:15 pm